The Appraisal Committee considered evidence submitted by the manufacturer of mifamurtide and a review of this submission by the Evidence Review Group (ERG). The evidence for the efficacy of ...

The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Discover comprehensive details about Mifamurtide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Review the side-effects of Mifamurtide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor ...

IDM Pharma, Inc. Receives Recommendation for Approval of Mifamurtide for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for ...

First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. If you have advanced osteosarcoma, you may be able to have surgery to remove as much of the ...

Co announces the presentation of updated survival data from the Phase 3 mifamurtide clinical trial. The trial was part of a National Cancer Institute funded cooperative group study conducted by the ...

In the submission, the manufacturer compared mifamurtide as an add-on treatment to postoperative multi-agent adjuvant chemotherapy (3- or 4-agent adjuvant chemotherapy using high-dose methotrexate, ...